Arcadia Biosciences annual meeting drew 52.3% of outstanding shares represented

Arcadia Biosciences held its annual shareholder meeting on Sept. 10, 2026.

Shareholders adopted the 2026 Omnibus Equity Incentive Plan, replacing the expired 2015 plan; prior awards remain governed by the earlier plan.

Authorization was granted for potential issuance of common stock upon exercise of Series A-1 Preferred Investment Options from the June 12, 2026 private placement.

Investors endorsed an amendment allowing the board to execute a reverse stock split before June 30, 2027, at a 1-for-2 to 1-for-10 ratio.

Ratification passed for Ramirez Jimenez International CPAs as independent auditor for the year ending Dec. 31, 2026; meeting adjournment authority was also approved.